Halozyme to offer $1.3B in convertible notes; extends credit facility to $750M

HALOZYME THERAPEUTICS, INC.

Amended credit facility: commitments increased to $750M, maturity extended to Nov 5, 2030; no outstanding borrowings.
Proposes $650M 2031 notes and $650M 2032 notes; option for additional $100M each.
Net proceeds partly fund capped call transactions to reduce potential dilution upon conversion.
Plans to repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes via private deals.
Remaining proceeds for general corporate purposes, including working capital and acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.